MERIT-HF: Impact of ß-blocker dose on outcomes in patients with heart failure

In a post hoc subgroup analysis, the MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure) researchers examined the relation of ß-blocker dose to clinical outcomes.¹ Randomized placebo-controlled trials of ß-blocker therapy in heart failure show that patients treated with ß-blockade benefit with reductions in morbidity and mortality.^2-5 However, because not all patients in these studies reached the targeted ß-blocker dose, clinicians have questioned whether maximum doses are necessary to benefit from treatment. The current analysis has produced additional information on this issue.

References are listed at the end of the Data Alert.

DA13.ppt

Download DA13.ppt (6 slides - 0.9MB)

Data_Alert.pdf (0.3MB)

CR HF MERIT Metoprolol subgroup XL

Related at vwbg.org

MERIT-HF: Benefits of ß-blockade in women with heart failure and reduced left ventricular function

Under-representation of women in heart failure (HF) clinical trials has created uncertainty about the efficacy of various treatment strategies in women.

New ACC/AHA Guidelines: Expanding the Role of Angiotensin Receptor Blockade in Heart Failure with LV Dysfunction

The 2005 ACC/AHA updated guidelines for the treatment of chronic HF and LV dysfunction in adults include an expanded role for ARBs as alternative therapy to ACEIs in selected patients and as added neurohormonal therapy in patients with persistent symptoms who are receiving optimal treatment.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).

More related